CholremCholesterol & arterial science

Programs

One mechanism. A widening frontier.

Every program below is the same molecule doing the same thing: removing cholesterol from where it does harm. The stage labels are honest, because the honesty of the later rows is what makes the first rows believable.

Stage key.  Human imaging published human imaging data   Human cases published human case data   Observational published human observational data   Potential independent preclinical science plus Cholrem user reports

Human imaging

Coronary atherosclerosis

What the science says

Bonn, 2016: HPβCD regresses established plaque in animal models and increases cholesterol efflux from human plaque tissue.

What Cholrem has seen

Severe three-vessel coronary disease (70–99% stenoses on invasive angiogram) reduced to patent arteries on CT after eleven months of nightly therapy, with no surgery and no medication. Case series across multiple patients showing plaque regression on CT coronary angiography.

Next

Randomised CT coronary angiography trial of plaque volume. Lead program.

Human imaging

Coronary artery calcification

What the science says

Calcium is the scaffold left behind in healed plaque. No drug class has ever produced a net fall in coronary calcium score in a controlled trial.

What Cholrem has seen

Serial, scanner-matched Agatston scores falling in the majority of tracked patients, published 2026. An early rise during active regression followed by decline, a pattern Cholrem predicted and then observed.

Next

Per-lesion volume and density analysis; inclusion as a secondary endpoint in the randomised trial.

Human cases

Peripheral arterial disease

What the science says

The same foam-cell and crystal biology drives leg artery disease. Limb ischaemia is the amputation pathway.

What Cholrem has seen

Published cases of peripheral plaque regression and symptomatic improvement in walking and limb perfusion in Cholrem’s case series. Users with critical limb disease report improvement where the alternative was surgery.

Next

Ankle-brachial index and duplex ultrasound cohort. A program with the potential to keep limbs attached.

Human cases

Carotid disease

What the science says

Carotid plaque is the stroke pathway, and the most accessible plaque to image serially with ultrasound.

What Cholrem has seen

Cholrem’s 2021 study documented carotid plaque reduction on ultrasound within weeks of intravenous therapy. Carotid cases recur through the later series.

Next

Serial carotid ultrasound sub-study; stroke-prevention positioning.

Observational

Symptoms & quality of life

What the science says

Plaque regression should translate to fewer symptoms: less angina, more exercise tolerance, better energy.

What Cholrem has seen

A 125-person, 12-week self-monitored observational study published in 2025 reported symptomatic and quality-of-life improvement across the cohort.

Next

Patient-reported outcomes embedded in the randomised trial.

Observational

Lipids & metabolic health

What the science says

HPβCD was expected to act on plaque directly rather than on blood lipids. The lipid effect was a bonus.

What Cholrem has seen

Falls in serum cholesterol and triglycerides observed repeatedly across Cholrem’s papers, from the 2021 paper onward, in people taking no lipid-lowering medication.

Next

Mechanistic study of the triglyceride effect, which independent science did not predict and which may open its own program.

Potential

Cognition & Alzheimer’s disease

What the science says

Weill Cornell, 2012: HPβCD cleared amyloid and restored memory in Alzheimer’s-model mice. A Phase 2 intravenous HPβCD study in early Alzheimer’s has been registered by another company, and MIT has licensed cyclodextrin technology for ApoE4-carrier Alzheimer’s disease.

What Cholrem has seen

Cholrem’s users consistently and spontaneously report clearer thinking, better recall and improved mental energy. These are unsolicited reports over years of use, and they match the mechanism. These reports are documented in Cholrem’s 2025 observational study, where clearer thinking and sharper memory were among the most frequently reported benefits.

Next

Structured cognitive assessment in Cholrem’s user registry, then a formal cognition cohort. The largest opportunity on this page.

Potential

Vascular & sexual function

What the science says

Erectile function is an early and sensitive marker of small-vessel endothelial health. What clears large arteries should help small ones.

What Cholrem has seen

Users report improvement in erectile function as one of the earliest noticeable changes on therapy. The signal is consistent and the market is enormous. In Cholrem’s 2025 observational study, 59% of the men had erectile dysfunction at the start, and many reported significant improvement by week twelve.

Next

Validated questionnaire study within the registry.

Potential

Stroke recovery & microvascular disease

What the science says

Independent 2026 work shows HPβCD clears the myelin-debris foam cells that stall repair after neurological injury, and small-vessel disease shares the same cholesterol biology.

What Cholrem has seen

An area Cholrem is watching closely as independent science develops. No Cholrem data yet.

Next

Collaboration with academic neurology groups.

Every row is the same molecule

A partner who funds the coronary trial is buying the key to the whole table.